Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

被引：0
|
作者：
Pignata, S.
Scambia, G.
Savarese, A.
Sorio, R.
Breda, E.
Ferrandina, G.
Gebbia, V.
Musso, P.
Gallo, C.
Perrone, F.
机构：
[1] Ist Nazl Tumori, Naples, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Ist Regina Elena, I-00161 Rome, Italy
[4] CRO, Aviano, Italy
[5] Osped Fatebenefratelli, Rome, Italy
[6] Univ Palermo, Casa Cura La Maddalena, Palermo, Italy
[7] Osped Oncol, M Ascoli ARNAS, Palermo, Italy
[8] Univ Naples 2, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Preliminary activity results of the MITO-2 randomized multicenter trial
    Pignata, S.
    Scambia, G.
    Savarese, A.
    Breda, E.
    Sorio, R.
    Lombardi, A. Vernaglia
    Gebbia, V.
    Scollo, P.
    Lorusso, D.
    Morabito, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial
    Pignata, S.
    Scambia, G.
    Savarese, A.
    Sorio, R.
    Breda, E.
    Ferrandina, G.
    Gebbia, V.
    Musso, P.
    Gallo, C.
    Perrone, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [3] Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Preliminary safety results of the MITO-2 randomized multicenter trial.
    Pignata, S
    Scambia, G
    Savarese, A
    Zagonel, V
    Gebbia, V
    Scollo, P
    de Vivo, R
    Rossi, E
    Di Maio, M
    Perrone, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 458S - 458S
  • [4] Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial
    Pignata, S.
    Scambia, G.
    Savarese, A.
    Sorio, R.
    Breda, E.
    Legge, F.
    Gebbia, V.
    Musso, P.
    Gallo, C.
    Perrone, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [5] Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial
    Pignata, Sandro
    Scambia, Giovanni
    Ferrandina, Gabriella
    Savarese, Antonella
    Sorio, Roberto
    Breda, Enrico
    Gebbia, Vittorio
    Musso, Pietro
    Frigerio, Luigi
    Del Medico, Pietro
    Lombardi, Alessandra Vernaglia
    Febbraro, Antonio
    Scollo, Paolo
    Ferro, Antonella
    Tamberi, Stefano
    Brandes, Alba
    Ravaioli, Alberto
    Valerio, Maria Rosaria
    Aitini, Enrico
    Natale, Donato
    Scaltriti, Laura
    Greggi, Stefano
    Pisano, Carmela
    Lorusso, Domenica
    Salutari, Vanda
    Legge, Francesco
    Di Maio, Massimo
    Morabito, Alessandro
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27) : 3628 - 3635
  • [6] CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL
    Pignata, S.
    Scambia, G.
    Savarese, A.
    Sorio, R.
    Breda, E.
    Ferrandina, G.
    Murgia, V.
    Tamberi, S.
    Signoriello, S.
    Di Maio, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 304 - 304
  • [7] Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial
    Pignata, S.
    Scambia, G.
    Savarese, A.
    Breda, E.
    Sorio, R.
    Pisano, C.
    Lorusso, D.
    Cognetti, F.
    Lombardi, A. Vernaglia
    Gebbia, V.
    Scollo, P.
    Morabito, A.
    Signoriello, G.
    Perrone, F.
    ONCOLOGY, 2009, 76 (01) : 49 - 54
  • [8] Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
    Pignata, Sandro
    Scambia, Giovanni
    Savarese, Antonella
    Breda, Enrico
    Scollo, Paolo
    De Vivo, Rocco
    Rossi, Emanuela
    Gebbia, Vittorio
    Natale, Donato
    Del Gaizo, Filomena
    Naglieri, Emanuele
    Ferro, Antonella
    Musso, Pietro
    D'Arco, Alfonso Maria
    Sorio, Roberto
    Pisano, Carmela
    Di Maio, Massimo
    Signoriello, Giuseppe
    Annunziata, Annalisa
    Perrone, Francesco
    BMC CANCER, 2006, 6 (1)
  • [9] Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
    Sandro Pignata
    Giovanni Scambia
    Antonella Savarese
    Enrico Breda
    Paolo Scollo
    Rocco De Vivo
    Emanuela Rossi
    Vittorio Gebbia
    Donato Natale
    Filomena Del Gaizo
    Emanuele Naglieri
    Antonella Ferro
    Pietro Musso
    Alfonso Maria D'Arco
    Roberto Sorio
    Carmela Pisano
    Massimo Di Maio
    Giuseppe Signoriello
    Annalisa Annunziata
    Francesco Perrone
    BMC Cancer, 6
  • [10] Combination paclitaxel plus Carboplatin versus paclitaxel with alternating Carboplatin and cisplatin as first line treatment for advanced ovarian cancer (AOC)
    Aravantinos, G
    Fountzilas, G
    Kosmides, P
    Stathopoulos, GP
    Pavlidis, N
    Dimopoulos, MA
    Bafaloukos, D
    Papakostas, P
    Papadimitriou, C
    Nikolaides, G
    Skarlos, DV
    ANNALS OF ONCOLOGY, 1998, 9 : 66 - 66
12345